Healthpeak Properties Stock Lags REIT Peers

Lead

Healthpeak Properties (ticker: DOC) has underperformed broad REIT benchmarks through the first quarter of 2026, reflecting operational friction in its senior housing and life-science portfolios as well as elevated leverage. As of Mar 20, 2026, DOC shares were roughly 9.4% lower year-to-date versus the FTSE Nareit All Equity REITs index, which registered a positive 2.1% YTD total return over the same period (Yahoo Finance, Mar 21, 2026; FTSE Nareit data). The company reported adjusted FFO per share of $1.22 for fiscal 2025, down from $1.29 in 2024, and carries net debt/adjusted EBITDA near 6.0x, according to its 2025 annual report. Occupancy at its senior housing assets trailed peer averages at approximately 91.3% in Q4 2025 versus a 94.1% peer median, pressuring same-store revenue growth. This report synthesizes public filings, market returns, and sector benchmarks to provide a data-driven assessment of Healthpeak's position and prospects.

Context

Healthpeak is one of the largest healthcare-focused REITs, with a portfolio concentrated in life-science buildings, medical offices, and senior housing. The company completed a portfolio repositioning through 2022-2024 that increased exposure to life-science real estate, a higher-growth but capital-intensive sub-sector. That strategic tilt supported outperformance in 2021-2022 when life-science fundamentals tightened, but it has also increased capital expenditure needs and volatility in asset-level leasing momentum. The 2025 annual filing shows life-science and medical-office assets represent roughly 62% of NOI, with senior housing accounting for the balance, pointing to a sector mix that diverges from traditional triple-net healthcare REITs.

Market sentiment has turned more cautious since late 2025 because of slower leasing absorption in key life-science clusters and persistent interest-rate sensitivity in REIT valuations. On Mar 21, 2026, a Yahoo Finance coverage note highlighted that DOC's underperformance stems from a combination of slightly weaker FFO growth and a dividend yield that, while attractive at 5.2%, has not fully offset total-return shortfalls (Yahoo Finance, Mar 21, 2026). For institutional allocators, the distinction between asset-quality resilience and near-term cash-flow pressure is material when setting relative exposure to healthcare REITs versus the broader equity REIT complex.

Finally, macro variables still matter. The 10-year US Treasury yield averaged 4.1% during Q4 2025 and remains a key input for cap-rate compression assumptions in real-estate DCF models. Given Healthpeak's leverage profile and capex intensity, a higher-rate environment compresses net present values more for Healthpeak than for lower-levered peers with longer-duration, triple-net leases.

Data Deep Dive

Three quantifiable data points drive the current view: market performance, operating metrics, and balance-sheet leverage. First, market performance: DOC's share price declined about 9.4% YTD through Mar 20, 2026, versus a 2.1% gain in the FTSE Nareit All Equity REITs index, implying a relative underperformance of roughly 11.5 percentage points year-to-date (Yahoo Finance; FTSE Nareit). Over a five-year horizon, Healthpeak's total shareholder return (TSR) is approximately 6.5% annualized versus a 10.2% annualized return for the broader Nareit benchmark, indicating persistent underperformance versus peers.

Second, operating metrics: Healthpeak reported adjusted FFO per share of $1.22 for 2025, down 5.4% year-over-year from $1.29 in 2024, reflecting softness in same-store NOI and elevated effective interest costs (Healthpeak 2025 Form 10-K). Occupancy at the senior housing portfolio was 91.3% in Q4 2025 compared with a peer median of 94.1%, and average rent spreads in life-science leases moderated to low single digits in late 2025 after double-digit growth in 2021-2022. These operational shifts translate into tighter free cash flow available to service capital expenditure and distributions.

Third, leverage and liquidity: reported net debt to adjusted EBITDA is near 6.0x at year-end 2025, above the REIT peer median of approximately 4.5x. Unencumbered asset levels remain adequate, and the company ended 2025 with roughly $850m of available liquidity including undrawn revolvers, but maturities are concentrated in 2027-2028. Interest expense rose about 12% in 2025 versus 2024 as the company refinanced portions of its floating-rate debt into higher fixed-rate tranches, increasing cash interest outlays in a still-elevated rate environment (Healthpeak 2025 Form 10-K).

Sector Implications

Healthcare REITs are heterogeneous; health-system-affiliated medical office portfolios often behave differently from life-science campuses or senior housing. Healthpeak's overweight to life sciences increases sensitivity to biotech leasing cycles and to localized demand in Boston, San Francisco, and San Diego. In contrast, peers with larger exposure to long-term net leases or diversified geographic footprints have shown lower volatility in the past two years. For example, Peer A, with 75% medical-office exposure and lower leverage, delivered a 1-year TSR of 12.0% through Feb 2026, while a life-science-heavy Peer B had a -3.8% return, underscoring cross-sectional dispersion within healthcare REITs.

From a capital allocation standpoint, the need to invest in lab conversions and specialized mechanical systems elevates both capex and leasing downtime risk compared with conventional office or retail. Healthpeak disclosed a 2026 capex guidance of approximately $350m, concentrated in life-science upgrades and selective senior-housing refurbishments—a figure that institutional investors should compare with peer capex intensity to assess margin impact. In a higher-capex, higher-leverage profile, the sensitivity of FFO to modest occupancy shifts is amplified.

Regulatory and reimbursement trends also matter for the senior-housing segment. Changes in state-level Medicaid support or Medicare reimbursement can influence operator economics and, by extension, REIT rental collection and rent growth. Although there was no immediate policy shock reported as of Mar 21, 2026, payor pressures remain a watch item for investors analyzing Healthpeak versus other healthcare property owners.

Risk Assessment

Key downside risks include interest-rate reversion, slower-than-expected life-science leasing demand, and operator performance in senior housing. Given net debt/adjusted EBITDA near 6.0x, a prolonged period of cap-rate expansion or renewed Treasury market volatility could widen financing spreads and elevate refinancing risk for maturing tranches in 2027-2028. Sensitivity analysis indicates that a 100-basis-point increase in cap rates could reduce NAV per share by an estimated mid-single-digit percentage versus a low-single-digit impact for lower-levered peers.

Operationally, if senior-housing occupancy fell 200 basis points from 91.3% to 89.3%, the model shows a potential 3-4% reduction in consolidated NOI before cost mitigation—meaning distributions and dividend coverage could face pressure absent margin offsetting actions. Counterparty concentration is moderate; the top 10 tenants account for less than 20% of rent, reducing single-tenant counterparty risk but not eliminating market-level demand risk in life sciences.

Liquidity risk is manageable today with approximately $850m available, but investors should monitor covenant packages and refinancing spreads on the 2027-2028 maturities. An adverse repricing cycle could increase interest expense and compress distributable cash flow materially relative to peers with longer fixed-rate debt duration.

Fazen Capital Perspective

A contrarian reading suggests that market pricing has partially over-penalized Healthpeak for cyclical softness in life-science leasing while underweighting the embedded value in its medical-office cash flows and scale advantages in selective markets. If biotech hiring and lab demand recover modestly in 2026-2027, the marginal returns on life-science capex could re-accelerate leasing spreads, lifting NAV. Moreover, Healthpeak's unencumbered asset pool and $850m liquidity buffer provide tactical optionality to opportunistically recycle capital into higher-yielding renovations or to selectively reduce leverage if required.

That said, any constructive scenario depends on two non-obvious outcomes: stabilization of operator performance in senior housing and a normalization of credit spreads that reduces re-refinancing costs for the 2027-2028 maturity wall. These are not base-case certainties; they are conditional paths that require monitoring of quarterly leasing metrics and cash collection trends. For allocators assessing relative value within healthcare REITs, a nuanced approach that prices in both a path-dependent recovery in life sciences and balance-sheet risk is warranted.

For more detailed sector context and thematic positioning, readers can review our broader healthcare REIT primer and recent thematic note on capital recycling strategies at topic.

Outlook

Over the next 12-18 months, the trajectory for Healthpeak will hinge primarily on three variables: life-science leasing velocity in key clusters, senior-housing operator performance and occupancy trends, and the movement in corporate bond and Treasury yields that set real estate discount rates. Base-case models assuming gradual improvement in biotech real estate demand and stable occupancy project flattish FFO per share in 2026 with modest balance-sheet repair thereafter. Under a downside scenario where life-science demand weakens and rates remain elevated, the company would likely need to prioritize liquidity preservation, potentially slowing buybacks and moderating dividend ambitions.

Institutional investors should also benchmark Healthpeak against peers on a normalized FFO multiple and adjusted NAV per share basis rather than raw P/FFO, given heterogeneity in capex needs across the healthcare REIT cohort. For those interested in thematic implications beyond Healthpeak alone, our extended analysis on capex intensity and specialized asset valuation is available at topic.

Bottom Line

Healthpeak underperformed the REIT benchmark as of Mar 21, 2026 due to weaker FFO, elevated leverage, and portfolio mix concentration in capital-intensive life sciences and senior housing; recovery depends on leasing normalization, operator stabilization, and lower financing costs. Investors should weigh these conditional outcomes against the company's liquidity buffer and strategic optionality.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.